While preclinical application of GPA33-targeting antibodies employing bispecific T-cell engaging antibodies [27], immunotoxins [28–30], and click-mediated radiotherapy [31] showed promising results in tumor models and xenografts, clinical trials did not provide successful response rates. Here, GPA33 is linked to neoplasm.